The Rockefeller University has licensed its portfolio of broadly neutralizing antibodies (bNAbs) against HIV—including the two clinical-stage agents 3BNC117 and 10-1074 to Gilead Sciences (GILD). These investigational agents have the potential for use in HIV long-acting therapies for treatment and prevention, as well as cure strategies.
Rockefeller University Intellectual Property
The research center has been busy the past few years developing HIV bNAbs, a class of immunotherapy agents that were initially derived from HIV infected individuals with a strong anti-HIV immunologic response and were thus designed to target HIV, mainly originating from the latent viral reservoir. The research center’s initial preclinical and clinical research reveals that HIV bNAbs can produce an enhanced, prolonged immune response to HIV, representing a promising new approach for HIV treatment or prevention in combination with other long-acting agents, or prolonged virologic remission in the absence of antiretroviral use.
This licensing agreement offers an additional pathway for innovations in Gilead’s HIV pipeline in areas of evolving and unmet medical needs.
In this deal, Gilead acquires exclusive global licenses to develop and commercialize Rockefeller’s full portfolio of HIV bNAbs. The university will receive an upfront payment and is eligible to receive cumulative milestone payments, as well as royalties on net sales. Rockefeller will retain the right to perform non-clinical and early-stage clinical research on the portfolio of HIV antibodies. These antibodies haven’t been approved, and their safety and efficacy haven’t been proven yet.
The Rockefeller University
The Rockefeller University is a private graduate university in New York City. It focuses primarily on the biological and medical sciences, and provides doctoral and postdoctoral education. Rockefeller is the oldest biomedical research institute in the United States.Source: BusinessWire